Emerald Advisers LLC Sells 52,710 Shares of Trevi Therapeutics, Inc. $TRVI

Emerald Advisers LLC lessened its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 2.8% during the 1st quarter, Holdings Channel reports. The firm owned 1,839,566 shares of the company’s stock after selling 52,710 shares during the quarter. Emerald Advisers LLC’s holdings in Trevi Therapeutics were worth $21,946,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TRVI. AQR Capital Management LLC lifted its holdings in Trevi Therapeutics by 20.4% during the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock valued at $174,000 after purchasing an additional 4,688 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Trevi Therapeutics by 31.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after buying an additional 10,445 shares during the last quarter. Millennium Management LLC grew its stake in Trevi Therapeutics by 356.3% during the first quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after buying an additional 642,830 shares during the last quarter. Strs Ohio acquired a new stake in shares of Trevi Therapeutics during the first quarter worth approximately $52,000. Finally, Creative Planning increased its holdings in shares of Trevi Therapeutics by 17.5% during the second quarter. Creative Planning now owns 20,247 shares of the company’s stock worth $111,000 after buying an additional 3,016 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TRVI shares. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, May 20th. Morgan Stanley reiterated an “overweight” rating and issued a $20.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. D. Boral Capital reissued a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research note on Friday, April 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Monday, April 20th. Finally, Stifel Nicolaus set a $30.00 price target on shares of Trevi Therapeutics in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $22.67.

Trevi Therapeutics Price Performance

TRVI stock opened at $16.52 on Tuesday. The company has a 50 day moving average price of $15.55 and a 200 day moving average price of $13.18. Trevi Therapeutics, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $20.15. The stock has a market capitalization of $2.35 billion, a PE ratio of -51.62 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, equities analysts expect that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.